Roy A Whitfield is Director of NEKTAR THERAPEUTICS. Currently has a direct ownership of 216,250 shares of NKTR, which is worth approximately $268,150. The most recent transaction as insider was on Jun 14, 2023, when has been sold 30,000 shares (Common Stock) at a price of $0.57 per share, resulting in proceeds of $17,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 216K
0% 3M change
0% 12M change
Total Value Held $268,150

ROY A WHITFIELD Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 14 2023
SELL
Open market or private sale
$17,100 $0.57 p/Share
30,000 Reduced 12.18%
216,250 Common Stock
Sep 16 2022
BUY
Grant, award, or other acquisition
-
10,200 Added 3.98%
246,250 Common Stock
Sep 22 2021
BUY
Grant, award, or other acquisition
-
10,200 Added 4.14%
236,050 Common Stock
Sep 16 2021
BUY
Exercise of conversion of derivative security
$552,000 $13.8 p/Share
40,000 Added 15.05%
225,850 Common Stock
Dec 30 2020
SELL
Bona fide gift
-
51,500 Reduced 21.7%
185,850 Common Stock
RAW

Roy A Whitfield

Director
San Francisco, CA

Track Institutional and Insider Activities on NKTR

Follow NEKTAR THERAPEUTICS and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NKTR shares.

Notify only if

Insider Trading

Get notified when an Nektar Therapeutics insider buys or sells NKTR shares.

Notify only if

News

Receive news related to NEKTAR THERAPEUTICS

Track Activities on NKTR